Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2014 · 10-Q
Revenue$31.83M$31.83M−25.8% vs Q1 2013 Net Income-$1.61M-$1.61MN/M vs Q1 2013 EPS Diluted-$0.11-$0.11N/M vs Q1 2013 Gross Profit$5,120,000−39.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$6,463,000N/M Free Cash Flowderived-$6,977,000N/M Margins · derivedGross margin16.1%−3.7 pt vs Q1 2013
Operating margin-1.3%−6.5 pt vs Q1 2013
Net margin-5.1%−10.0 pt vs Q1 2013
ended Mar 31, 2014 · filed May 8, 2014 · 38 d after period end